Performance of a Rapid SARS-CoV-2 Antigen Detection Assay in Symptomatic Children

Nader Shaikh\(^a\), MD, MPH, Eric J. Friedlander\(^d\), MD, MPH, Patrick J. Tate\(^d\), MD, Hui Liu\(^a\), MS, Chung-Chou Ho Chang\(^c\), PhD, Alan Wells\(^b\), MD, DMSc, Alejandro Hoberman\(^a\), MD

Affiliations: Departments of \(^a\)Pediatrics, \(^b\)Pathology and \(^c\)Biostatistics, University of Pittsburgh School of Medicine and \(^d\)Children’s Community Pediatrics; UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA.

Address correspondence to: Nader Shaikh, MD, MPH, UPMC Children’s Hospital of Pittsburgh, One Children's Hospital Drive, 4401 Penn Ave, Pittsburgh, PA 15224, nader.shaikh@chp.edu, 412-692-8111 (phone), 412-692-8516 (fax)

Conflict of interest Disclosures: The authors have no conflicts to declare.

Funding/Support: No funding was received in support of this study.

Abbreviations: FDA: United States Food and Drug Administration; PCR: Polymerase Chain Reaction; CI: Confidence Interval

Contributors' Statement:
Drs. Shaikh conceptualized the study, designed the study, analyzed the data, and drafted the initial manuscript.

Dr. Hoberman conceptualized the study, designed the study, analyzed the data, and reviewed and revised the manuscript.

Drs. Tate and Friedlander collected data and reviewed and revised the manuscript.

Dr. Wells, Hui Liu, and Dr. Chung-Chou Ho Chang analyzed the data and reviewed and revised the manuscript.

All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.
INTRODUCTION

Abbott BinaxNOW™—a bedside lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen—is widely available under FDA emergency use authorization for detection of SARS-CoV-2 in symptomatic patients within 7 days of symptom onset. Its diagnostic performance in symptomatic children has not been evaluated.

METHODS

Cross-sectional study of symptomatic children ≤20 years presenting for care to one of two primary care practices in December of 2020 during which time COVID rates were particularly high (1927 cases per 100,000 and 26% all tests performed were positive).1 The University of Pittsburgh Institutional Review Board approved the study.

Per our institution’s guidelines at the time of the study, we tested consecutive children with symptoms for <7 days presenting with one of the following: cough, shortness of breath, difficulty breathing, loss of smell or taste, severe respiratory illness; or two of the following: known exposure to COVID-19, fever or chills, congestion or runny nose, body aches, fatigue, headache, sore throat, nausea, vomiting, or diarrhea. Assuming 25% of children would test positive for SARS-CoV-2 and that the sensitivity and specificity of BinaxNow™ would be close to 85%, we estimated needing 196 children to produce 95% confidence intervals no wider than +/-10% around test sensitivity.2

Two nasal (middle turbinate) swabs were obtained from each patient, one from each nostril. One was used for in-office BinaxNow™; one trained reader visually interpreted test cards (any visible band was considered positive). The second specimen was placed in transport media and submitted for qualitative real-time polymerase chain reaction (PCR) for SARS-CoV-2 RNA using Roche Cobas or Hologic Panther platforms at a local Clinical Laboratory Improvement Amendments approved laboratory.
We calculated accuracy of BinaxNOW™ using PCR results as the reference standard using Stata 16. Because previous studies have suggested relatively higher viral loads in younger children, we explored the effect of age on test accuracy.

RESULTS

A total of 199 children aged 2 months to 20 years were included; 39 had positive PCR for SARS-CoV-2. Sensitivity and specificity of BinaxNow™ were 0.85 (95% confidence interval: 0.70-0.94) and 0.91 (0.86-0.95), respectively (Table 1). The accuracy of the test was higher (p=.008) in children aged <7 years; in this age group, the sensitivity (CI) and specificity (CI) of the test were 1.00 (0.72-1.00) and 0.92 (0.84-0.97), respectively.

DISCUSSION

We provide data on the accuracy of BinaxNOW™ for SARS-CoV-2 in symptomatic children. The test does not seem particularly useful in children 7-20 years because of its suboptimal combination of sensitivity and specificity. In children <7 years, although specificity of the test was suboptimal, its high sensitivity might be useful in ruling out COVID-19. If our findings are confirmed by others, children <7 years with a negative BinaxNOW™ result could be allowed to return to daycare or preschool. However, positive results would need to be confirmed with a PCR test given the test’s high false positive rate.

Two studies examined accuracy of BinaxNOW™. The first included a convenience sample of adults, 84% of whom were asymptomatic; the second enrolled a community sample (73% asymptomatic; 6% <18 years). These studies reported sensitivities in the 89%-96% range and specificities of >99%; no differences were apparent according to age or presence of symptoms. In contrast, our study included only symptomatic children with suspected COVID-19 and found similar
sensitivity (except in those <7 years) but substantially lower specificity. Differences between results might be due to differences in test interpretation in the previous studies (interpreting the test retrospectively using scanned images, using at least two readers, disregarding partial bands). The differing spectrum of patients could also influence accuracy.⁶

Strengths of our study include determining test performance in the same setting as it would be used in practice. Limitations include lack of cycle threshold data for the PCR test. In conclusion, the use of the BinaxNow™ rapid antigen test must consider potentially high rates of false positives, and the age of the target population before being used as a stand-alone assay.

References
**Table 1.** Accuracy of BinaxNOW™ for SARS-CoV-2 infection according to age

<table>
<thead>
<tr>
<th>No. children</th>
<th>No. with SARS-CoV-2</th>
<th>Sensitivity (95% CI)(^a)</th>
<th>Specificity (95% CI)(^a)</th>
<th>Positive predictive value (95% CI)(^a)</th>
<th>Negative predictive value (95% CI)(^a)</th>
</tr>
</thead>
<tbody>
<tr>
<td>In children of all ages</td>
<td>199</td>
<td>39</td>
<td>85 (70-94)</td>
<td>91 (86-95)</td>
<td>70 (55-83)</td>
</tr>
<tr>
<td>In children &lt;7 years</td>
<td>89</td>
<td>11</td>
<td>100 (72-100)</td>
<td>92 (84-97)</td>
<td>65 (38-86)</td>
</tr>
<tr>
<td>In children 7-20 years</td>
<td>110</td>
<td>28</td>
<td>79 (59-92)</td>
<td>90 (82-96)</td>
<td>73 (54-88)</td>
</tr>
</tbody>
</table>

\(^a\)95% confidence interval
Performance of a Rapid SARS-CoV-2 Antigen Detection Assay in Symptomatic Children
Nader Shaikh, Eric J. Friedlander, Patrick J. Tate, Hui Liu, Chung-Chou Ho Chang, Alan Wells and Alejandro Hoberman
Pediatrics originally published online May 26, 2021; originally published online May 26, 2021;

Updated Information & Services
including high resolution figures, can be found at:
http://pediatrics.aappublications.org/content/early/2021/06/08/peds.2021-050832.citation

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.aappublications.org/site/misc/Permissions.xhtml

Reprints
Information about ordering reprints can be found online:
http://www.aappublications.org/site/misc/reprints.xhtml
Performance of a Rapid SARS-CoV-2 Antigen Detection Assay in Symptomatic Children
Nader Shaikh, Eric J. Friedlander, Patrick J. Tate, Hui Liu, Chung-Chou Ho Chang, Alan Wells and Alejandro Hoberman

*Pediatrics* originally published online May 26, 2021; originally published online May 26, 2021;

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://pediatrics.aappublications.org/content/early/2021/06/08/peds.2021-050832.citation